<DOC>
	<DOC>NCT00288522</DOC>
	<brief_summary>The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of moderate intensity.</brief_summary>
	<brief_title>Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Patients with autoimmune thyroid disease and whose centre's medical records confirm the presence of euthyroidism for at least two months before being included into the study Thyroidassociated ophthalmopathy diagnosed a minimum of six months before his/her participation in the study, well documented in the centre's medical records and based on the moderate intensity of thyroidassociated ophthalmopathy in the worst eye Patients whose ophthalmopathy activity has been demonstrated by a positive octreoscan The patient presents compressive optical neuropathy signs which require immediate surgical treatment or suffers from serious intensity thyroid ophthalmopathy The patient has been treated with radioiodine for his/her thyroid disturbance in the past 6 months The patient's thyroidassociated ophthalmopathy has been treated previously (except for drops and local measures) or is planned to be treated with radioiodine or thyroidectomy for his/her autoimmune thyroid disease during the study or suffers from myopia, glaucoma or any other eye disease which could modify the ophthalmological progress The patient is a smoker of more than 5 cigarettes per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>